Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.
Identifieur interne : 000426 ( PubMed/Checkpoint ); précédent : 000425; suivant : 000427Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.
Auteurs : S Y Park [Corée du Sud] ; J S Lee [Corée du Sud] ; J S Son [Corée du Sud] ; J H Ko [Corée du Sud] ; K R Peck [Corée du Sud] ; Y. Jung [Corée du Sud] ; H J Woo [Corée du Sud] ; Y S Joo [Corée du Sud] ; J S Eom [Corée du Sud] ; H. Shi [Corée du Sud]Source :
- The Journal of hospital infection [ 1532-2939 ] ; 2019.
Descripteurs français
- KwdFr :
- Adulte, Antiviraux (administration et posologie), Antiviraux (effets indésirables), Effets secondaires indésirables des médicaments (anatomopathologie), Effets secondaires indésirables des médicaments (épidémiologie), Femelle, Humains, Incidence, Infections à coronavirus (), Jeune adulte, Lopinavir (administration et posologie), Lopinavir (effets indésirables), Mâle, Personnel de santé, Prophylaxie après exposition (), Ribavirine (administration et posologie), Ribavirine (effets indésirables), Ritonavir (administration et posologie), Ritonavir (effets indésirables), Sujet âgé, Études rétrospectives.
- MESH :
- administration et posologie : Antiviraux, Lopinavir, Ribavirine, Ritonavir.
- anatomopathologie : Effets secondaires indésirables des médicaments.
- effets indésirables : Antiviraux, Lopinavir, Ribavirine, Ritonavir.
- épidémiologie : Effets secondaires indésirables des médicaments.
- Adulte, Femelle, Humains, Incidence, Infections à coronavirus, Jeune adulte, Mâle, Personnel de santé, Prophylaxie après exposition, Sujet âgé, Études rétrospectives.
English descriptors
- KwdEn :
- Adult, Aged, Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Coronavirus Infections (prevention & control), Drug-Related Side Effects and Adverse Reactions (epidemiology), Drug-Related Side Effects and Adverse Reactions (pathology), Female, Health Personnel, Humans, Incidence, Lopinavir (administration & dosage), Lopinavir (adverse effects), Male, Post-Exposure Prophylaxis (methods), Retrospective Studies, Ribavirin (administration & dosage), Ribavirin (adverse effects), Ritonavir (administration & dosage), Ritonavir (adverse effects), Young Adult.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Lopinavir, Ribavirin, Ritonavir.
- chemical , adverse effects : Antiviral Agents, Lopinavir, Ribavirin, Ritonavir.
- epidemiology : Drug-Related Side Effects and Adverse Reactions.
- methods : Post-Exposure Prophylaxis.
- pathology : Drug-Related Side Effects and Adverse Reactions.
- prevention & control : Coronavirus Infections.
- Adult, Aged, Female, Health Personnel, Humans, Incidence, Male, Retrospective Studies, Young Adult.
Abstract
An effective post-exposure prophylaxis (PEP) strategy may limit the spread of infection. However, there is no consensus regarding PEP for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. This study assessed the efficacy of ribavirin and lopinavir/ritonavir as PEP for healthcare workers (HCWs) exposed to patients with severe MERS-CoV pre-isolation pneumonia. The safety of the PEP regimen was assessed. HCWs with high-risk exposure to MERS-CoV pre-isolation pneumonia were retrospectively enrolled. HCWs who received PEP therapy were classified into the PEP group. PEP therapy was associated with a 40% decrease in the risk of infection. There were no severe adverse events during PEP therapy.
DOI: 10.1016/j.jhin.2018.09.005
PubMed: 30240813
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:30240813Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.</title><author><name sortKey="Park, S Y" sort="Park, S Y" uniqKey="Park S" first="S Y" last="Park">S Y Park</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Lee, J S" sort="Lee, J S" uniqKey="Lee J" first="J S" last="Lee">J S Lee</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul, South Korea. Electronic address: rem324@naver.com.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Son, J S" sort="Son, J S" uniqKey="Son J" first="J S" last="Son">J S Son</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Ko, J H" sort="Ko, J H" uniqKey="Ko J" first="J H" last="Ko">J H Ko</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Peck, K R" sort="Peck, K R" uniqKey="Peck K" first="K R" last="Peck">K R Peck</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Jung, Y" sort="Jung, Y" uniqKey="Jung Y" first="Y" last="Jung">Y. Jung</name><affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, Anyang, Gyeonggi, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, Anyang, Gyeonggi</wicri:regionArea><wicri:noRegion>Gyeonggi</wicri:noRegion></affiliation></author><author><name sortKey="Woo, H J" sort="Woo, H J" uniqKey="Woo H" first="H J" last="Woo">H J Woo</name><affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Dongtan Sacred Heart Hospital, Hallym University School of Medicine, Hwasung, Gyeonggi, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Dongtan Sacred Heart Hospital, Hallym University School of Medicine, Hwasung, Gyeonggi</wicri:regionArea><wicri:noRegion>Gyeonggi</wicri:noRegion></affiliation></author><author><name sortKey="Joo, Y S" sort="Joo, Y S" uniqKey="Joo Y" first="Y S" last="Joo">Y S Joo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Occupational and Environmental Medicine, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, Anyang, Gyeonggi, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Occupational and Environmental Medicine, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, Anyang, Gyeonggi</wicri:regionArea><wicri:noRegion>Gyeonggi</wicri:noRegion></affiliation></author><author><name sortKey="Eom, J S" sort="Eom, J S" uniqKey="Eom J" first="J S" last="Eom">J S Eom</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Shi, H" sort="Shi, H" uniqKey="Shi H" first="H" last="Shi">H. Shi</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30240813</idno><idno type="pmid">30240813</idno><idno type="doi">10.1016/j.jhin.2018.09.005</idno><idno type="wicri:Area/PubMed/Corpus">000775</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000775</idno><idno type="wicri:Area/PubMed/Curation">000775</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000775</idno><idno type="wicri:Area/PubMed/Checkpoint">000426</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000426</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.</title><author><name sortKey="Park, S Y" sort="Park, S Y" uniqKey="Park S" first="S Y" last="Park">S Y Park</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Lee, J S" sort="Lee, J S" uniqKey="Lee J" first="J S" last="Lee">J S Lee</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul, South Korea. Electronic address: rem324@naver.com.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Son, J S" sort="Son, J S" uniqKey="Son J" first="J S" last="Son">J S Son</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Ko, J H" sort="Ko, J H" uniqKey="Ko J" first="J H" last="Ko">J H Ko</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Peck, K R" sort="Peck, K R" uniqKey="Peck K" first="K R" last="Peck">K R Peck</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Jung, Y" sort="Jung, Y" uniqKey="Jung Y" first="Y" last="Jung">Y. Jung</name><affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, Anyang, Gyeonggi, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, Anyang, Gyeonggi</wicri:regionArea><wicri:noRegion>Gyeonggi</wicri:noRegion></affiliation></author><author><name sortKey="Woo, H J" sort="Woo, H J" uniqKey="Woo H" first="H J" last="Woo">H J Woo</name><affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Dongtan Sacred Heart Hospital, Hallym University School of Medicine, Hwasung, Gyeonggi, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Dongtan Sacred Heart Hospital, Hallym University School of Medicine, Hwasung, Gyeonggi</wicri:regionArea><wicri:noRegion>Gyeonggi</wicri:noRegion></affiliation></author><author><name sortKey="Joo, Y S" sort="Joo, Y S" uniqKey="Joo Y" first="Y S" last="Joo">Y S Joo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Occupational and Environmental Medicine, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, Anyang, Gyeonggi, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Occupational and Environmental Medicine, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, Anyang, Gyeonggi</wicri:regionArea><wicri:noRegion>Gyeonggi</wicri:noRegion></affiliation></author><author><name sortKey="Eom, J S" sort="Eom, J S" uniqKey="Eom J" first="J S" last="Eom">J S Eom</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Shi, H" sort="Shi, H" uniqKey="Shi H" first="H" last="Shi">H. Shi</name><affiliation wicri:level="3"><nlm:affiliation>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author></analytic><series><title level="j">The Journal of hospital infection</title><idno type="eISSN">1532-2939</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (adverse effects)</term><term>Coronavirus Infections (prevention & control)</term><term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term><term>Drug-Related Side Effects and Adverse Reactions (pathology)</term><term>Female</term><term>Health Personnel</term><term>Humans</term><term>Incidence</term><term>Lopinavir (administration & dosage)</term><term>Lopinavir (adverse effects)</term><term>Male</term><term>Post-Exposure Prophylaxis (methods)</term><term>Retrospective Studies</term><term>Ribavirin (administration & dosage)</term><term>Ribavirin (adverse effects)</term><term>Ritonavir (administration & dosage)</term><term>Ritonavir (adverse effects)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (effets indésirables)</term><term>Effets secondaires indésirables des médicaments (anatomopathologie)</term><term>Effets secondaires indésirables des médicaments (épidémiologie)</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Infections à coronavirus ()</term><term>Jeune adulte</term><term>Lopinavir (administration et posologie)</term><term>Lopinavir (effets indésirables)</term><term>Mâle</term><term>Personnel de santé</term><term>Prophylaxie après exposition ()</term><term>Ribavirine (administration et posologie)</term><term>Ribavirine (effets indésirables)</term><term>Ritonavir (administration et posologie)</term><term>Ritonavir (effets indésirables)</term><term>Sujet âgé</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Lopinavir</term><term>Ribavirin</term><term>Ritonavir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Lopinavir</term><term>Ribavirin</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Lopinavir</term><term>Ribavirine</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Lopinavir</term><term>Ribavirine</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Post-Exposure Prophylaxis</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Health Personnel</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Retrospective Studies</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Infections à coronavirus</term><term>Jeune adulte</term><term>Mâle</term><term>Personnel de santé</term><term>Prophylaxie après exposition</term><term>Sujet âgé</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">An effective post-exposure prophylaxis (PEP) strategy may limit the spread of infection. However, there is no consensus regarding PEP for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. This study assessed the efficacy of ribavirin and lopinavir/ritonavir as PEP for healthcare workers (HCWs) exposed to patients with severe MERS-CoV pre-isolation pneumonia. The safety of the PEP regimen was assessed. HCWs with high-risk exposure to MERS-CoV pre-isolation pneumonia were retrospectively enrolled. HCWs who received PEP therapy were classified into the PEP group. PEP therapy was associated with a 40% decrease in the risk of infection. There were no severe adverse events during PEP therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30240813</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2939</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of hospital infection</Title><ISOAbbreviation>J. Hosp. Infect.</ISOAbbreviation></Journal><ArticleTitle>Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.</ArticleTitle><Pagination><MedlinePgn>42-46</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0195-6701(18)30484-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhin.2018.09.005</ELocationID><Abstract><AbstractText>An effective post-exposure prophylaxis (PEP) strategy may limit the spread of infection. However, there is no consensus regarding PEP for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. This study assessed the efficacy of ribavirin and lopinavir/ritonavir as PEP for healthcare workers (HCWs) exposed to patients with severe MERS-CoV pre-isolation pneumonia. The safety of the PEP regimen was assessed. HCWs with high-risk exposure to MERS-CoV pre-isolation pneumonia were retrospectively enrolled. HCWs who received PEP therapy were classified into the PEP group. PEP therapy was associated with a 40% decrease in the risk of infection. There were no severe adverse events during PEP therapy.</AbstractText><CopyrightInformation>Copyright © 2018 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>S Y</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul, South Korea. Electronic address: rem324@naver.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>J H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peck</LastName><ForeName>K R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, Anyang, Gyeonggi, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>H J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Dongtan Sacred Heart Hospital, Hallym University School of Medicine, Hwasung, Gyeonggi, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joo</LastName><ForeName>Y S</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Occupational and Environmental Medicine, Hallym University Sacred Heart Hospital, Hallym University School of Medicine, Anyang, Gyeonggi, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eom</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Hosp Infect</MedlineTA><NlmUniqueID>8007166</NlmUniqueID><ISSNLinking>0195-6701</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="Y">Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056990" MajorTopicYN="N">Post-Exposure Prophylaxis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Healthcare worker</Keyword><Keyword MajorTopicYN="N">High-risk exposure</Keyword><Keyword MajorTopicYN="N">Middle East respiratory syndrome coronavirus</Keyword><Keyword MajorTopicYN="N">Outbreak</Keyword><Keyword MajorTopicYN="N">Post-exposure prophylaxis</Keyword><Keyword MajorTopicYN="N">Pre-isolation pneumonia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>07</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>09</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30240813</ArticleId><ArticleId IdType="pii">S0195-6701(18)30484-5</ArticleId><ArticleId IdType="doi">10.1016/j.jhin.2018.09.005</ArticleId><ArticleId IdType="pmc">PMC7114948</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Int J Antimicrob Agents. 2014 Dec;44(6):528-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25288266</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2016 Apr;22(4):647-56</Citation><ArticleIdList><ArticleId IdType="pubmed">26981708</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect. 2013 Dec;67(6):606-16</Citation><ArticleIdList><ArticleId IdType="pubmed">24096239</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2015 Jun;15(6):629</Citation><ArticleIdList><ArticleId IdType="pubmed">26008827</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Nov;14(11):1090-1095</Citation><ArticleIdList><ArticleId IdType="pubmed">25278221</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Corée du Sud</li></country><region><li>Région capitale de Séoul</li></region><settlement><li>Séoul</li></settlement></list><tree><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Park, S Y" sort="Park, S Y" uniqKey="Park S" first="S Y" last="Park">S Y Park</name></region><name sortKey="Eom, J S" sort="Eom, J S" uniqKey="Eom J" first="J S" last="Eom">J S Eom</name><name sortKey="Joo, Y S" sort="Joo, Y S" uniqKey="Joo Y" first="Y S" last="Joo">Y S Joo</name><name sortKey="Jung, Y" sort="Jung, Y" uniqKey="Jung Y" first="Y" last="Jung">Y. Jung</name><name sortKey="Ko, J H" sort="Ko, J H" uniqKey="Ko J" first="J H" last="Ko">J H Ko</name><name sortKey="Lee, J S" sort="Lee, J S" uniqKey="Lee J" first="J S" last="Lee">J S Lee</name><name sortKey="Peck, K R" sort="Peck, K R" uniqKey="Peck K" first="K R" last="Peck">K R Peck</name><name sortKey="Shi, H" sort="Shi, H" uniqKey="Shi H" first="H" last="Shi">H. Shi</name><name sortKey="Son, J S" sort="Son, J S" uniqKey="Son J" first="J S" last="Son">J S Son</name><name sortKey="Woo, H J" sort="Woo, H J" uniqKey="Woo H" first="H J" last="Woo">H J Woo</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000426 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000426 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:30240813
|texte= Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:30240813" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |